Pharma & Finance Consulting

Beerse ·KBO/BCE: BE 0791.674.606

Loading dossier…

Year closed	Due by	Filed	Variance	Reference
31-12-2025	31-07-2026	nothing on record	not filed	-
31-12-2024	31-07-2025	30-06-2025	31 d early	2025-00199872
31-12-2023	31-07-2024	19-07-2024	12 d early	2024-00272866

Metric	This company	Sector median	Position in the sector
Solvency	61.5%	60.5%	better than 51% of 12484 sector peers
Net result	€9k	€31k	better than 27% of 12486 sector peers
Equity	€27k	€63k	better than 29% of 12492 sector peers
Gross operating margin	€19k	€52k	better than 24% of 12472 sector peers
Total assets	€44k	€124k	better than 17% of 12485 sector peers

Line item	Code	2024
Balance sheet, Assets
TOTAL ASSETS	20/58	€44k
Fixed assets	21/28	€11k
Tangible fixed assets	22/27	€11k
Current assets	29/58	€32k
Amounts receivable within one year	40/41	€19k
Cash & bank	54/58	€13k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€44k
Equity	10/15	€27k
Contributions / capital	10/11	€3k
Reserves	13	€25k
Accumulated profits (losses)	14	€0
Amounts payable	17/49	€17k
Amounts payable within one year	42/48	€16k
Trade debts payable within one year	44	€553
Income statement
Gross operating margin	9900	€19k
Operating result	9901	€14k
Financial income	75	€89
Financial charges	65	€873
Result before taxes	9903	€13k
Income taxes	67/77	€4k
Net result for the period	9904	€9k
Result to be appropriated	9905	€9k

Summary

Legal nameNL	Pharma & Finance Consulting
AbbreviationNL	P&F Consulting